LONDON – Summit plc announced the opening of the phase III trial of ridinilazole in the treatment of Clostridium difficile infections, with the first patient being dosed in the U.S. on Tuesday. The orally administered drug becomes only the second antibiotic that currently is in phase III development to have a novel mechanism of action.